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Background/aim: Mastocytosis is a heterogeneous group of diseases characterized by the abnormal infiltration of mast cells in the
skin and sometimes other organs. This study aimed to compare the demographic, clinical, and histopathological findings of cutaneous
mastocytosis with onset in children and in adults.
Materials and methods: Patients diagnosed with cutaneous mastocytosis in 2 different dermatology clinics between 2007 and 2011
were included in the study. Demographic characteristics of the patients as well as localization and type of the cutaneous lesions, presence
of symptoms, Darier’s sign, family history, systemic involvement, and histopathological evaluations were retrospectively examined.
Results: Out of the 30 cases of cutaneous mastocytosis, 60% of patients were male (n = 18) and 40% were female (n = 12). Twenty-two
patients had childhood-onset mastocytosis (≤15 years) and 8 patients had adult-onset mastocytosis. The onset of the disease occurred
before the age of 2 years in all cases of childhood onset. Patients with adult-onset mastocytosis had statistically significantly more
systemic involvement than those with childhood-onset mastocytosis (P < 0.05).
Conclusion: Cutaneous mastocytosis is a benign disease in children without systemic involvement and is usually sporadic.
Key words: Cutaneous mastocytosis, children, adult

1. Introduction
Mastocytosis is a heterogeneous group of diseases and occurs
as a result of abnormal proliferation of mast cells involving
the bone marrow, liver, spleen, lymph nodes, gastrointestinal
system, and skin. All clinical types of mastocytosis are rarely
seen. The most commonly involved organ is the skin (1,2).
Based on the World Health Organization classification,
cutaneous mastocytosis (CM) is divided into 3 groups:
maculopapular type CM (MPCM), which was previously
named urticaria pigmentosa according to traditional
classification; diffuse CM (DCM), and solitary CM (SM).
MPCM also has special forms including plaque form,
nodular form, and telangiectasia macularis eruptiva perstans
(TMEP) (3,4). Mastocytosis can be classified as being of
childhood onset (less than 15 years old) and adult onset
(more than 15 years old) based on its clinical appearance and
course (5). In this study, we compared demographic features,
clinical, and histopathological findings of childhood- and
adult-onset of CM.

2. Materials and methods
We retrospectively evaluated 30 patients that were
clinically and histopathologically diagnosed with CM
in 2 different dermatology clinics between April 2007
and August 2011. Patients’ age, sex, age of onset of CM,
clinical types of CM, clinical symptoms, distributions of
lesions, presence of Darier’s sign, family history, systemic
involvement, histopathological findings, treatments, and
follow-up findings were obtained from the charts. For
an assessment of systemic involvement, total cell count,
liver function test, kidney function test, bone X-ray,
abdominal ultrasonography, and bone marrow biopsy (in
adult patients) were performed. A phone interview was
conducted with the patients to obtain more information
on clinical courses. Data analysis was performed with SPSS
15.0. The Mann–Whitney U test was used for categorical
variability relationship analysis. A P-value of less than 0.05
was considered statistically significant.
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itching. In the adult group, 7 patients had MPCM (87.5%)
and 1 patient (12.5%) had TMEP. Itching was the most
common symptom (7 patients; 87.5%) in the adult
group. The difference in the incidence of itching between
the 2 groups was not statistically significant (P > 0.05).
Other symptoms, including flushing, headache, fatigue,
abdominal pain, nausea, vomiting, and diarrhea, were not
detected in either group.
In the childhood group, the most common types of
lesions were macular (n = 8) and maculopapular (n =
7). Bullous lesions developed in 2 cases (1 case: SM; 1
case: MPCM). The most commonly involved areas were
the trunk (n = 6) and the upper and lower limbs (n = 4).
Three childhood patients with MPCM developed facial
involvement, as well. Three childhood patients with SM
only developed trunk involvement. The most common
types of lesions in the adult group were maculopapular
lesions (n = 5) followed by macular lesions (n = 3). The
most commonly involved area was the trunk plus upper
and lower limbs (n = 5) and only the trunk (n = 2) in the
adult group. No facial or neck involvement was detected
in the adult group. There was no statistically significant
difference in the lesions’ morphology and locations
between the 2 groups (P > 0.05). The involved areas in the
childhood and adult groups are shown in Figure 5.

Number of patients

Number of patients

3. Results
Of these 30 patients, 22 (73.3%) were in the childhood
group and 8 (26.7%) were in the adult group. Sixty percent
of the patients (n = 18) were male and 40% of them (n =
12) were female. The male-to-female ratio was 1:0.6.
In the childhood group, 12 (54.5%) were male and 10
(45.5%) were female. The mean age was 2.4 ± 2.1 years
(ranging from 7 months to 9 years). The age of onset of
disease was 5.8 ± 4.5 months (ranging from 1 month to
18 months). The male-to-female ratio was 1:0.8. In the
adult group, 6 patients were male (75%) and 2 were female
(25%). The mean age was 33 ± 7 years (ranging from 19
years to 41 years). The male-to-female ratio was 1:0.3.
In the childhood group, all patients developed their
first lesion before the age of 2 years. Seventy-seven percent
of the patients (17 cases) developed the lesions within 6
months following birth. None had a lesion at birth. The
distribution of childhood patients according to age of
onset of the lesions is summarized in Figure 1. In the adult
group, the mean of age of lesion onset was 30 ± 7 years
(ranging from 17 years to 39 years). Distribution of adult
patients according to lesion onset age is shown in Figure 2.
In the childhood group, 19 patients had MPCM
(Figure 3) and 3 patients had SM (Figure 4). Of the
symptoms, 72.7% (15 patients) of the patients developed
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Figure 1. Age distribution of childhood-onset mastocytosis.

Figure 2. Age distribution of adult-onset mastocytosis.

Figure 3. Maculopapular cutaneous mastocytosis. Diffuse redbrown macula and papules on the trunk and extremities.

Figure 4. Solitary mastocytoma. Erythematous plaque with
eroded vesicles on the trunk.
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Sites of lesions

Figure 5. Distribution of lesion sites in childhood- and adult-onset mastocytosis.

Darier’s sign was positive in 19 patients (86.4%) in the
childhood group. Three patients with negative Darier’s
sign had MPCM. All patients with SM had positive
Darier’s sign. Darier’s sign was positive in 75% of the adult
group. The 2 adult patients with negative Darier’s sign had
TMEP and MPCM clinical types. There was no statistically
significant difference in the incidence of positivity of
Darier’s sign between the 2 groups (P > 0.05).
No family history was present in the childhood or
adult patients. The systemic involvement work-up was
negative in the childhood group. Bone marrow biopsy
showed systemic involvement in 2 adult patients with CM.
Systemic involvement was statistically significantly higher
in the adult group than the childhood group (P < 0.05).
The skin biopsy from the childhood and adult patients
with CM showed mast cell infiltration without cellular
atypia around the blood vessels and dermis (Figure 6a).
Metachromatic granules in the mast cells were detected
with Toluidine blue staining (Figure 6b). An intense
cytoplasmic staining with C-kit (CD117) of mast cells was
obtained with immunohistochemical staining (Figure 6c).
The patients were treated with mast cell stabilizers such
as H1 and H2 antihistamines, ketotifen, cromolyn sodium,
and low- and moderate-potency topical steroids. Two
adult patients (TMEP and MPCM) were also treated with
narrow-band ultraviolet B. Of the 2 patients with systemic
involvement, 1 was treated with interferon and the other
was closely monitored without any additional treatment.
However, most of the patients did not come back for
follow-up visits regularly. Three childhood patients were
reached over the phone. The lesions were completely
resolved in 2 of the patients (1 case of MPCM, 1 case of
SM) and the lesions were partially resolved with no new
lesions in 1 of the patients (MPCM). Two adult patients
treated with phototherapy stopped treatment at the end
of first and second month of the treatment, respectively.
There was no change in their lesions. Demographic and
clinical features of the adult and childhood patients are
shown in the Table.
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4. Discussion
Mastocytosis is a rare disease most commonly seen in
infants and children. The incidence of the disease shows
variability between studies (1/200–8000) (6,7). One of the
studies from Turkey performed by Seraslan et al. detected
a high prevalence rate 1:234 (8).
In our study, 73.3% of the patients had childhood onset
of the disease. This rate was 64% in Middelkamp et al.’s
study including adult- and childhood-onset CM cases
(5). In our study, the male/female ratio was 1:0.8 in the
childhood group and 1:0.3 in the adult group. Although
the frequency of disease was higher in males, it was not
statistically significant. Our findings were consistent with
the previous results in which the male/female ratio was
1.5–1.8/1 (5,6,9). However, the female frequency was
higher in other studies (male/female ratio of 1/1.5–1.8)
(8,10).
Skin lesions usually occur at early ages in cutaneous
mastocytosis. In Middelkamp et al.’s study, 50% of the
lesions started before the age of 2, 14% of them between
2 and 15 years, and 36% in adult years (5). In the study by
Akoglu et al., the lesions started during the first 6 months
of life and 78.2% of lesions started before 13 months. In
addition, no congenital clinical type was detected in these
studies (10). In our study, 73.3% of lesions started before
age of 2. The rest of the lesions (26.7%) started after the age
of 17. The peak incidence in the childhood group was the
age of 1 and the percentage of lesion onset during the first 6
months of age was 77%. No congenital form was detected.
Our findings were consistent with previous results.
The clinical types of cutaneous mastocytosis
are MPCM, DCM, and SM. The special forms of MPCM
include the plaque form, nodular form, and TMEP (3,4).
The frequency of subtypes shows differences in different
studies. Previous studies reported that 80%–85.7% of
patients developed MPCM and 20%–21.4% of them had
SM (8,10). In our study, the frequency of MPCM was
86.4% and that of SM was 13.6% in the childhood group.
TMEP was not detected in the childhood group.
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Figure 6. Staining of samples. a) Intense mast cell infiltration in the dermis (H&E, 200×). b) Metachromatic staining of the mast cells
with toluidine blue in the dermis (200×). c) Intense positive staining with CD117 (immunoperoxidase, 200×).

The frequency of MPCM was 87.5% in the adult group.
One patient with TMEP (12.5%) was detected in the adult
group. The most frequently seen clinical type was MPCM
in our study. The skin lesions can be red or brown papules,
plaque, or nodules. MPCM usually does not involve the
palmoplantar region, face, and scalp (2,11,12). However, 3
patients with MPCM developed facial involvement in our
study. There was no significant difference in the frequency
of clinical types in the childhood and adult groups. In our
study, 3 patients (13.6%) had SM in the childhood group.
These SM lesions that were located on the trunk were
consistent with the literature. Diffuse CM is a rare and
severe form of CM (1,13). There was no DCM case in our
study. We only detected 1 case of TMEP in the adult group.
Family history is rare in mastocytosis. Around 50
family cases have been reported, but typical genetic
penetrance has not been described (14–18). There was no
family history in our study.

Itching, flushing, headache, vertigo, fatigue, and
gastrointestinal symptoms including abdominal pain,
nausea, vomiting, and diarrhea can be seen in mastocytosis.
The symptoms can result in the release of mast cell
mediators, particularly histamines (5,8). Middelkamp et
al. found symptoms including itching, flushing, abdominal
pain, diarrhea, and headache in 50% of childhood patients
and 61% of adult patients (5). In our study, itching was
detected in 72.7% of the childhood group and 87.5% of
the adult group. There was no significant difference in the
frequency of itching between the 2 groups (P > 0.05).
Darier’s sign is an erythematous and urticarial flare
surrounding the lesions that occurs as a result of mast cell
degranulation and inflammatory mediator release induced
by minor trauma (14). Serarslan et al. found Darier’s sign
positivity in 92.9% of patients and Akoglu et al. detected
Darier’s sign positivity in 89.5% of patients (8,10). In
our study, we found Darier’s sign positivity in 86.4% of
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Table. Demographic and clinical data of the patients with cutaneous mastocytosis.
Childhood-onset mastocytosis (n = 22)

(%)

Adult-onset mastocytosis (n = 8)

(%)

Female

10

45.5

2

25

Male

12

54.5

6

75

Age

2.4 ± 2.1 years (7 months to 9 years)

33 ± 7 years (19–41 years)

Age of onset

0.5 ± 0.4 (1–18 months)

30 ± 7 (17–39 years)

Cutaneous form
MPCM
TMEP
DCM
SM

19
–
3

86.4
–
–
13.6

7
1
–
–

36.4
31.8
13.6
13.6
9
4.5

3
5
–
–
–
–

87.5
12.5
–
–

Type of lesions
Macule
Macule-papule
Papule
Plaque
Bulla
Nodule

8
7
3
3
2
1

Symptoms
None
Pruritus

6
15

27.3
72.7

1
7

12.5
87.5

Family history

–

–

–

–

Darier’s sign
Positive
Negative

19
3

86.4
13.6

6
2

75
25

–

2

25

Systemic involvement –

37.5
62.5
–
–
–
–

MPCM: Maculopapular cutaneous mastocytosis, TMEP: telangiectasia macularis eruptiva perstans, DCM: diffuse cutaneous
mastocytosis, SM: solitary cutaneous mastocytosis.

the childhood patients and 75% of the adult patients;
the difference between these groups was not statistically
significant (P > 0.05).
The histopathological examination of cutaneous
mastocytosis showed intense mast cell infiltration
in the dermis and around blood vessels. In MPCM,
mast cells usually distribute scatteredly around blood
vessels. In SM, mast cells usually cluster around blood
vessels and occasionally in the subcutaneous tissue.
Mast cell infiltration can be shown by hematoxylin and
eosin staining. Giemsa stain and toluidine blue can
be used to stain metachromatic granules in mast cells.
Histochemical staining such as chloroacetate esterase or
immunohistochemical stain such as C-kit (CD117) can be
used for further investigations (8,14).
Cutaneous mastocytosis usually recovers spontaneously
and rarely needs to be treated. The first treatment step
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is to avoid triggering factors that can cause mast cell
mediator release. Medical treatments include H1 and H2
antihistamines, mast cell stabilizers such as ketotifen and
cromolyn sodium, topical corticosteroids, PUVA, and
narrow band UVB therapy (2,3,14,19). In our study, H1
antihistamines, mast cell stabilizers, and topical steroids
were administered in the childhood cases and phototherapy
was applied in 2 adult cases. The treatment options for
systemic involvement are chemotherapy and interferon
alpha (20). In our study, systemic involvement was detected
in 2 (25%) adult patients. One was treated with interferon
therapy and the other was followed without any treatment.
There is a remarkable difference in terms of systemic
involvement and prognosis between childhood and adult
patients. Systemic changes are usually rare, transient, and
benign in childhood patients. In contrast to the childhood
patients, bone marrow disease, bone alterations, and
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gastrointestinal involvement are frequently seen in adult
patients and they usually show a progressive and chronic
course (6,21). In our study, systemic involvement was not
seen in the childhood patients and was only seen in 2 adult
patients.
In children, mastocytosis usually spontaneously
recovers by puberty (22). Our patients did not come to
follow-ups regularly. We reached the childhood patients
over the phone. Of 3 childhood patients, the skin lesions
were completely resolved in 2 patients (1 case of MPCM,
1 case of SM) and the lesions were diminished without
any new lesions in 1 patient with MPCM. Two of our
patients with adult onset CM (25%) developed systemic
involvement. Skin lesions were not detected in these
2 patients during the treatment course. These 2 adult
patients were reached over the phone and did not develop
any new lesions.
The evaluation of systemic involvement can be done by
the measurements of serum tryptase levels; a level above
20 ng/mL is a minor criterion of systemic mastocytosis (7).
The level of serum tryptase is important in diagnosis and

in clinical follow-up (7,23,24). Serum tryptase is usually
negative in patients with CM and is high in patients
with systemic mastocytosis (1). Increased levels of mast
cells derived from prostaglandin D2, heparin levels, and
increased serum and urine levels of N-methylhistamine
and n-methylimidazole acetic acid can be seen in patients
with systemic involvement (14). In our study, we could not
retrospectively assess serum tryptase, heparin, or urine
histamine metabolites levels in our patients.
In conclusion, our results from childhood- and adultonset CM patients were consistent with previous results.
Mastocytosis is a rare disease. The cutaneous form of
mastocytosis usually has a benign course, but systemic
involvement can be life-threatening. Childhood-onset
mastocytosis has a better prognosis than adult-onset
mastocytosis. Mastocytosis-related systemic involvement
is more common in adult-onset mastocytosis. Diagnosis
is usually made based on clinical findings. Further studies
involving a large number of patients with this rare disease
should be performed to develop new treatment approaches
for mastocytosis.
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